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Intratumoral CD4þ T Lymphodepletion Sensitizes
Poorly Immunogenic Melanomas to Immunotherapy
with an OX40 Agonist
Susumu Fujiwara1, Hiroshi Nagai1, Noriko Shimoura1, Shuntaro Oniki1, Takayuki Yoshimoto2 and
Chikako Nishigori1
Previous studies have shown that the antitumor effects of OX40 agonists depend on the immunogenicity of the
tumor and that poorly immunogenic tumors such as B16F10 melanomas do not respond to OX40 agonist treat-
ment. In this study, we have shown that intratumoral CD4þ T lymphodepletion sensitized poorly immunogenic
B16F10 melanomas to immunotherapy with an OX40 agonist. CD4þ T lymphodepletion dramatically altered the
tumor immune microenvironment, making it more susceptible to the antitumor effects of an OX40 agonist by
enhancing the accumulation of CD8þ T cells and natural killer (NK) cells in tumor tissue. However, unexpectedly,
the number of CD11bþGr-1þ myeloid-derived suppressor cells (MDSCs) within tumor tissues also significantly
increased as a result of CD4þT lymphodepletion. As a countermeasure against CD8þ T-cell accumulation, CCR2-
positive CD11bþGr-1int (monocytic) MDSCs predominantly increased. Treatment with an OX40 agonist under
CD4þ T lymphodepletion neither reduced MDSCs nor increased CD8þ T cells and NK cells, but further
enhanced the expression of cytotoxic molecules from tumor-infiltrating effector cells. Our results suggest that
combined immunotherapy using both an OX40 agonist and CD4þ T lymphodepletion could be a promising
therapeutic strategy for poorly immunogenic tumors and might be more effective if further combined with a
therapeutic strategy targeting MDSCs.
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INTRODUCTION
OX40 (CD134) is an B50-kDa glycoprotein with three
complete and one truncated cysteine-rich domains that are
characteristic of the TNF receptor superfamily. OX40 is
predominantly expressed on activated CD4þ T cells and
CD8þ T cells; however, other cell types, including natural
killer (NK) cells, NK T cells, neutrophils and CD4þFoxp3þ
regulatory T cells (Tregs), also express OX40 (Sugamura et al.,
2004; Croft, 2010; Ishii et al., 2010; Weinberg et al., 2011).
Several studies have shown that OX40 agonists have potent
antitumor activities in preclinical models (Weinberg et al.,
2000; Piconese et al., 2008; Jensen et al., 2010). However,
these antitumor effects were found to be dependent on the
immunogenicity of the tumor, because poorly immunogenic
tumors did not respond to OX40 agonist treatment (Kjaergaard
et al., 2000). A recent study highlighted the significance of
combining OX40 agonist therapy with other therapeutic
approaches for poorly immunogenic tumors (Hirschhorn-
Cymerman et al., 2009).
B16F10 melanoma cells are poorly immunogenic tumor
cells that originally spontaneously developed in C57BL/6 mice
and are thought to reflect the poor immunogenicity of
metastatic tumors in humans (Fidler, 1973). B16F10
melanoma, along with other poorly immunogenic tumors,
has been shown to be unresponsive to immunotherapy with
an OX40 agonist (Hirschhorn-Cymerman et al., 2009).
Accumulating evidence has shown that Tregs have a crucial
role in refractoriness to immunotherapy, and high levels of
Tregs have been detected in B16F10 tumor tissues (Kryczek
et al., 2007). Furthermore, other CD4þ regulatory T cells,
such as TR1 cells and Th3 cells, have also been shown to be
involved in tumor immune escape (Seo et al., 2001; Lo´pez
et al., 2006). As an OX40 agonist can activate not only
antitumor effector cells but also Tregs (Ruby et al., 2009; Xiao
et al., 2012), we hypothesized that depletion of the CD4þ
regulatory T cells in tumor tissue might sensitize B16F10
melanomas to immunotherapy with an OX40 agonist. To test
this possibility, we intratumorally administered an anti-CD4
mAb on day 7 after tumor inoculation. This approach
efficiently depleted Tregs, as well as helper T cells and other
CD4þ cells in B16F10 melanomas and sensitized these tumor
tissues to immunotherapy with an OX40 agonist. Interestingly,
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administration of just a single dose of anti-CD4 mAb into
B16F10 tissues dramatically altered the immune conditions
and augmented the infiltration of effector cells into the tumors.
However, unexpectedly, CD4þ T lymphodepletion also
augmented the recruitment of myeloid-derived suppressor
cells (MDSCs) into the tumor tissues. Finally, we analyzed
the mechanism by which combined treatment with an OX40
agonist and CD4þ T lymphodepletion exerts antitumor
effects.
RESULTS
Intratumoral CD4þ T lymphodepletion sensitizes poorly
immunogenic melanomas to immunotherapy with an OX40
agonist
Initially, we examined the antitumor effects of an OX40
agonist on poorly immunogenic B16F10 melanomas. As
shown in Figure 1a, treatment with OX40 agonist (starting
on day 0 after tumor inoculation) did not exert antitumor
effects. Next, we tested whether the OX40 agonist could exert
antitumor effects on B16F10 melanomas when combined
with cytokines that are involved in antitumor immunity.
Treatment with the OX40 agonist exerted significant anti-
tumor effects on IL-12 cDNA-transfected B16F10 melanomas,
but not on IL-27 cDNA-transfected B16F10 melanomas
(Figure 1b and c). In contrast, when combined with a single,
intratumoral administration of an anti-CD4 mAb (for CD4þ T
lymphodepletion), OX40 agonist treatment had significant
antitumor effects when started on day 7 (Figure 1d) or on day
0 (data not shown). Flow cytometric analysis showed that, in
control mice, which were intratumorally administered rat
IgG, 23.8% of the tumor-infiltrating mononuclear cells were
CD4þ after 7 days of administration, whereas in anti-CD4
mAb-treated mice, the proportion of CD4þ cells decreased to
0.67% at 7 days after administration of the anti-CD4 mAb.
The proportion of Treg cells (CD4þ Foxp3þ cells) among the
tumor-infiltrating mononuclear cells was 0.11% after anti-
CD4 mAb administration (vs. 7.4% in the control)
(Supplementary Figure S1 online). Other CD4þ cell popula-
tions (CD4þ F4/80þ cells, CD4þ CD11bþ cells, and CD4þ
CD11cþ cells) were barely (o0.3% of tumor-infiltrating
mononuclear cells) detected in the control tumor tissues on
day 14 and further decreased (to o0.03%) following anti-
CD4 mAb administration (data not shown). These results
indicated that the CD4-positive cells, including Tregs, in
tumor tissues were almost completely depleted on day 7 after
intratumoral injection of an anti-CD4 mAb.
Intratumoral CD4þ T lymphodepletion dramatically alters the
immune microenvironment in the tumor, making it more
susceptible to antitumor effects by enhancing the accumulation
of CD8þ T cells and NK cells
To clarify why intratumoral CD4þ T lymphodepletion sensi-
tizes B16F10 melanomas to immunotherapy with an OX40
agonist, we examined the cellular and humoral alterations
in CD4þ T-lymphodepleted tumor tissues. Flow cytometric
analysis showed that, in the control group, CD8þ T-cell
infiltration into B16F10 tumors was scarce and NK cell
infiltration was considerable. However, after CD4þ
T lymphodepletion, both CD8þ T cells and NK cells markedly
infiltrated into tumor tissues (Figure 2). The cytokine profile of
the tumor was also dramatically altered by CD4þ T lympho-
depletion. Cytokines with antitumor activities, such as IFN-g,
TNF-a, IL-2, and IL-12, were significantly upregulated by
CD4þ T lymphodepletion (Figure 3a). However, interestingly,
the expression of IL-23, which has been reported to inhibit
the accumulation of antitumor CD8þ T cells (Langowski
et al., 2006), significantly reduced. After CD4þ
T lymphodepletion, the expression levels of the immuno-
suppressive cytokine TGF-b did not change significantly
compared with the levels in control tumor tissues (data not
shown). However, the expression of IL-10 showed a tendency
to increase after CD4þ T lymphodepletion, although the
difference from the levels in control tumor tissues did
not reach statistical significance (Figure 3a). Both CXCL9
and CXCL10, that have antiangiogenic properties and the
chemoattractant effect of CXCR3þ lymphocytes, were signifi-
cantly upregulated by CD4þ T lymphodepletion. The number
of CXCR3þCD8þ T cells was significantly increased by
CD4þ T lymphodepletion (Figure 3b). In vivo depletion assays
showed that the antitumor effects induced by CD4þ
T lymphodepletion were mainly mediated by CD8þ T cells
(Supplementary Figure S2 online).
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Figure 1. Antitumor effects of an OX40 agonist on B16F10 melanomas. One-
hundred thousand tumor cells (a and d, B16F10 cells; b, IL-12 cDNA-transfected
B16F10 cells; c, IL-27 cDNA-transfected B16F10 cells) were subcutaneously
inoculated into the right flank of C57BL/6 mice (n¼5 per group) on day 0. (a–c)
Mice were intraperitoneally (i.p.) administered 1 mg of OX86 on day 0 and every
5 days thereafter. (d) Anti-CD4 mAb (500mg) was intratumorally injected only
once on day 7. OX86 was i.p. administered on day 7 and every 5 days
thereafter. The tumor size was measured as the product of the longest diameter
and the perpendicular diameter. The bars represent meanþ SEM (*Po0.05). The
data shown are from one of three individual experiments.
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CD11bþGr-1þ MDSCs within B16F10 tumor tissues also
increase following CD4þ T lymphodepletion
To further clarify the immune alteration induced as a result of
CD4þ T lymphodepletion, we examined CD11bþGr-1þ
MDSCs, which inhibit antitumor immunity (Peranzoni et al.,
2010; Gabrilovich et al., 2012). We originally expected that
the number of MDSCs within the tumor tissue would
decrease, because marked antitumor effects were achieved
mainly via CD8þ T cells after CD4þ T lymphodepletion
(Figure 1d and Supplementary Figure S2 online). Unexpect-
edly, CD11bþGr-1þ MDSCs (particularly CD11bþGr-1int
MDSCs but not CD11bþGr-1high MDSCs) significantly incre-
ased in CD4þT-lymphodepleted tumor tissues (Figure 4a).
Recent studies revealed that CCL2-CCR2 interaction has an
important role in the recruitment of MDSCs to tumor sites (Zhu
et al., 2011; Lesokhin et al., 2012). Indeed, after CD4þT
lymphodepletion, CCL2 markedly increased in the tumor
tissue (Figure 4b). In addition, the proportion of CCR2þ
MDSCs that infiltrated as a result of CD4þ T lymphodepletion
was higher than those for control tumors. The CD11bþGr-1int
MDSCs that increased following CD4þ T lymphodepletion
were mostly (490%) positive for CCR2 (Figure 4c). These
results suggest that CCL2-CCR2 interaction may be involved in
the increased MDSC recruitment into tumor tissue following
CD4þ T lymphodepletion.
The increase in the number of MDSCs is caused by the
infiltration of CD8þ T cells and not NK cells
We hypothesized that the recruitment of MDSCs into tumor
tissue induced by CD4þ T lymphodepletion may result from
the accumulation of effector cells. To verify the hypothesis, we
treated mice bearing B16F10 tumors with anti-CD8 mAb and
anti-asialoGM1 sera to deplete both CD8þ T cells and NK
cells, and then intratumorally administered an anti-CD4 mAb.
As shown in Figure 5a, MDSCs remarkably decreased follow-
ing depletion of both CD8þ T cells and NK cells. CCL2 was
also significantly decreased by depletion of these effector
cells. Both arginase-1 and inducible nitric oxide synthase
increased following CD4þ T lymphodepletion but decreased
following depletion of both CD8þ T cells and NK cells
(Figure 5b).
Next, we attempted to clarify which effector cells have a
crucial role in the recruitment of MDSCs. Depletion of CD8þ
T cells did not affect the recruitment of CD11bþGr-1high
MDSCs but reduced recruitment of CD11bþGr-1int MDSCs
(Figure 5c). Interestingly, depletion of NK cells did not affect
the recruitment of either MDSC population. These results
suggest that the recruitment of MDSCs by CD4þ T lympho-
depletion may result from the accumulation of CD8þ T cells
within the tumor tissue.
The antitumor effects of the OX40 agonist on CD4þ
T-lymphodepleted tumors are not related to the reduction in the
number of MDSCs and are mediated by enhancing the cytotoxic
activities of the effector cells
Recent studies revealed that an OX40 agonist could enhance
the infiltration of therapeutic effector cells, including CD8þ T
cells, and decrease MDSCs (Gough et al., 2008; Pardee et al.,
2010). Therefore, we determined whether the OX40 agonist
affected the MDSC populations, CD8þ T cells, and NK cells
in this model. As shown in Figure 6a, the OX40 agonist did
not decrease the MDSC populations. The OX40 agonist also
did not affect the proportion of CD8þ T cells that infiltrated
into the tumor tissues. The NK cell count showed a tendency
to decrease following OX40 agonist treatment; however, this
decrease was not statistically significant. Nevertheless, treat-
ment with the OX40 agonist markedly enhanced the expres-
sion of IL-2 and IFN-g in the tumor tissues (Figure 6b). In
addition, treatment markedly enhanced the expression of
granzyme B and perforin. These results indicate that the
OX40 agonist neither decreased the recruitment of MDSCs
nor increased that of effector cells, but augmented the
cytotoxic activities of the effector cells that accumulated in
the tumors as a result of CD4þ T lymphodepletion, thereby
further improving the antitumor efficacy of this model.
DISCUSSION
Recent accumulating evidence has shown that tumor immune
escape is related to increases in immunosuppressive popula-
tions such as Tregs and MDSCs within tumor tissues (Lindau
et al., 2013). In this study, we showed that CD4þ T
lymphodepletion dramatically altered the tumor cytokine
milieu and significantly augmented CD8þ T-cell and NK
cell infiltration in established, poorly immunogenic B16F10
melanoma tissues, which resulted in inhibition of tumor
growth. These dramatic changes could be partly attributed to
the concomitant depletion of Tregs within tumor tissues
following CD4þ T lymphodepletion (Supplementary Figure
S1 online). However, CD4þ T lymphodepletion also depletes
the T helper cells that have a crucial role in the priming,
expansion, and survival of CD8þ cytotoxic T lymphocytes.
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Figure 2. Intratumoral CD4þ T lymphodepletion enhances the accumulation
of CD8þ T cells and natural killer (NK) cells within the tumor tissue. B16F10
cells (105) were inoculated into the right flank of C57BL/6 mice (n¼ 5 per
group) on day 0, followed by intratumoral administration of 500mg of an anti-
CD4 mAb or control rat IgG on day 7. On day 14, the tumors were resected
and the numbers of CD8þ T cells (CD8þCD3þ ) and NK cells
(NK1.1þCD3 ) within tumor tissues were analyzed by flow cytometry. The
bars represent meanþ SEM (*Po0.05). Data shown are from one of three
individual experiments.
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Therefore, the initial infiltration of CD8þ T cells into tumor
tissues following CD4þ T lymphodepletion might not require
T helper cells. In our model, T helper cells might contribute to
the cytotoxic T lymphocyte-mediated antitumor effects in the
late period, because the number of CD4þ T cells in both
tumors and tumor-draining lymph nodes gradually increased
from B2 weeks after anti-CD4 mAb injection, concomitant
with decrease in the effect of the anti-CD4 mAb (data not
shown). Unexpectedly, the number of MDSCs in tumor tissues
also increased significantly following CD4þ T lymphodeple-
tion. MDSCs are a heterogeneous population of cells that
consists of polymorphonuclear, mononuclear, and immature
myeloid cells. In mice, MDSCs express the myeloid antigens
CD11b and Gr-1 and are classified as CD11bþGr-1high cells
(granulocytic MDSCs) or CD11bþGr-1int cells (monocytic
MDSCs). Granulocytic MDSCs suppress antigen-specific
CD8þ T cells, predominantly through the production of
reactive oxygen species. In contrast, monocytic MDSCs
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Figure 3. Intratumoral CD4þ T lymphodepletion dramatically alters the tumor immune microenvironment. Tumor tissues (day 14) were resected as
mentioned in the Figure 2 legend. (a) Total RNA was then extracted from the tissues. The mRNA expression levels of IFN-g, TNF-a, IL-2, IL-12p35, IL-23p19, IL-10,
CXCL9, and CXCL10 were determined by real-time RT-PCR and the expression levels relative to those of GAPDH mRNA (mean±SEM) are shown (**Po0.01).
Data shown are from one of three individual experiments. (b) The numbers of CXCR3-positive CD8þ T cells and natural killer (NK) cells within the tumor
tissues were analyzed by flow cytometry. The bars represent meanþ SEM (**Po0.01). Data shown are from one of two individual experiments.
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suppress CD8þ T cells, predominantly via inducible nitric
oxide synthase and arginase-1 enzymes and through the
production of reactive nitrogen species. Monocytic MDSCs
have been shown to be more suppressive than granulocytic
MDSCs in antigen-stimulated CD8þ T cells (Dolcetti et al.,
2010; Youn and Gabrilovich, 2010; Gabrilovich et al., 2012;
Lu and Gabrilovich, 2012). In our model, a larger number of
monocytic MDSCs infiltrated into tumors than granulocytic
MDSCs. The infiltration of monocytic MDSCs was almost
completely abrogated by in vivo depletion of CD8þ T cells
but not by depletion of NK cells (Figure 5c). Therefore,
monocytic MDSCs appear to increase in tumor tissues as a
specific response to the infiltration of CD8þ T cells. This
increase in the number of MDSC and the increase in IL-10
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Figure 4. The number of CCR2-positive myeloid-derived suppressor cells (MDSCs) increased in B16F10 tumor tissues after CD4þ T lymphodepletion. Tumor
tissues (day 14) were resected as mentioned in the Figure 2 legend. (a) The numbers of CD11bþGr-1þ MDSCs within tumor tissues were analyzed by flow
cytometry. The bars represent meanþ SEM (*Po0.05). Data shown are from one of four individual experiments. (b) CCL2 mRNA expression was determined by
real-time RT-PCR and has been shown relative to GAPDH mRNA expression (mean±SEM values) (**Po0.01). Data shown are from one of two individual
experiments. (c) The proportion of CCR2-positive MDSCs to total MDSCs within tumor tissues was analyzed by flow cytometry. The bars represent meanþ SEM
(***Po0.001). Data shown are from one of two individual experiments.
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expression (Figure 3a) are homeostatic responses for counter-
acting the antitumor immune reactions dominated by CD8þ T
cells. However, these MDSCs could not fully suppress the
antitumor immune reactions induced by intratumoral CD4þ T
lymphodepletion because the reactions were so strong.
Recent studies strongly suggest that CCL2-CCR2 interaction
has an important role in the recruitment of MDSCs to tumor
sites (Zhu et al., 2011; Gehad et al., 2012; Lesokhin et al.,
2012). In contrast, Fridlender et al. (2011) showed that CCL2
blockade inhibited tumor growth but did not affect the
recruitment of MDSCs. In fact, CCL2 blockade altered the
macrophage phenotype, thereby activating CD8þ T cells
(Fridlender et al., 2011). Recently, Zhao et al. (2012)
showed that TNF/TNF-R2 signaling has a crucial role in
MDSC accumulation within tumor tissues and that the major
source of TNF for MDSC accumulation could be the MDSCs
themselves. Furthermore, Sevko et al. (2012) showed that low-
dose cyclophosphamide therapy augmented the accumulation
of MDSCs in melanoma lesions concomitantly with increased
production of chronic inflammatory mediators, including TNF,
in the ret transgenic murine melanoma model. Indeed, as
shown in Figure 3a, TNF expression significantly increased in
tumor tissues following CD4þ T lymphodepletion. In addi-
tion, the expression of TNF was significantly reduced by
depletion of CD8þ T cells but not by depletion of NK cells
(data not shown). Although the initial trigger of TNF induction
in MDSCs has not yet been determined, infiltration of CD8þ T
cells into tumor tissues might be one of the key triggers.
In contrast to our results, Kjaergaard et al. (2000) showed
that the antitumor effects of an OX40 agonist on a GL261
mouse glioma were abrogated in mice depleted of either
CD4þ or CD8þ T cells. The reason for this discrepancy is not
known; however, we suppose that it might be caused by the
difference in the immunogenicity of tumor cells. The GL261
tumor was originally induced by intracranial injection of 3-
methylcholanthrene into C57BL/6 mice and is considered to
be moderately immunogenic (Szatma´ri et al., 2006). In highly
or moderately immunogenic tumors, CD8þ T cells might
easily accumulate and exert antitumor effects in cooperation
with CD4þ T cells. In fact, Giovarelli et al. (2000) showed
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Figure 5. The increase in the number of myeloid-derived suppressor cells (MDSCs) depends on the infiltration of CD8þ T cells. C57BL/6 mice (n¼ 5 per group)
were subcutaneously inoculated with 105 B16F10 cells on day 0. Some mice were intraperitoneally administered with anti-CD8 mAb and/or anti-asialo GM1 on
days 6 and 11. On day 7, anti-CD4 mAb or control rat IgG were intratumorally administered (a and c). On day 14, the numbers of CD11bþGr-1þ MDSCs within
tumor tissues were analyzed by flow cytometry. The bars represent meanþ SEM (*Po0.05). (b) CCL2, arginase-1, and inducible nitric oxide synthase (iNOS)
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that large numbers of both CD4þ T cells and CD8þ T cells
infiltrated an immunogenic variant of a TSA (a mouse mam-
mary adenocarcinoma) tumor, whereas both cells sparsely
infiltrated a parental poorly immunogenic TSA tumor.
Therefore, we hypothesized that, in highly or moderately
immunogenic tumors, treatment with an OX40 agonist can
activate both CD4þ T cells and CD8þ T cells that accumulate
within the tumor, thereby exerting their antitumor effects. In
fact, the OX40 agonist has been shown to directly costimulate
both CD4þ T cells and CD8þ T cells in vitro (Taraban et al.,
2002). Activated CD4þ T helper cells help control CD8þ
T-cell-dependent tumor eradication in vivo. Therefore,
antitumor effects on highly or moderately immunogenic
tumors would be abolished by depletion of either CD4þ or
CD8þ T cells. To verify this hypothesis, we examined the
antitumor effects of an OX40 agonist using a Cloudman S91
(clone M-3) murine melanoma (of DBA/2 origin), which is
generally considered to be more immunogenic than B16F10
melanomas. The Cloudman S91 melanoma had a slight
tendency to respond to OX40 agonist treatment alone in the
late stage; however, the difference from the control was not
statistically significant. Intratumoral CD4þ T lymphodepletion
caused more marked shrinkage of the S91 melanoma than of
the B16F10 melanoma. CD4þ T lymphodepletion plus
OX40 agonist treatment led the greatest reduction in
tumor size; however, the difference from the size of CD4þ
T-lymphodepleted tumors was not statistically significant, and
lymphodepletion plus OX40 agonist treatment led to rejection
of the tumors in some mice on day 27 (when mice in the other
groups showed no tumor rejection) (Supplementary Figure S3
online). Therefore, our hypothesis could not be verified;
however, it might result from the still poor immunogenicity
of Cloudman S91 melanoma. However, in another respect,
these results seem significant because CD4þ T lymphodeple-
tion plus OX40 agonist treatment was found to be effective for
melanomas with different immunogenicities and from different
mouse strains (Figure 1d and Supplementary Figure S3 online).
Although previous studies have shown that the therapeutic
efficacy of OX40 agonists depends on tumor immunogenicity,
this efficacy might be closely correlated with the degree of
CD8þ T-cell infiltration within tumor tissues. In fact, in
B16F10 tumors, the infiltration of CD8þ T cells has been
found to be sparse (Nagai et al., 2000a). Because the
antitumor effects of IL-12 gene-transfected B16F10 cells
were mediated by both CD8þ T cells and NK cells (Nagai
et al., 2000b), whereas those of IL-27 gene-transfected B16F10
cells were mediated by NK cells but not CD8þ T cells (Oniki
et al., 2006), the OX40 agonist might have induced antitumor
effects on IL-12 gene-transfected B16F10 cells but not on IL-27
gene-transfected B16F10 cells (Figure 1b and c). As CD4þ T
lymphodepletion permits the accumulation of CD8þ T cells in
B16F10 tumors (Figure 2), the OX40 agonist could exert
antitumor effects even if tumor cells are poorly immunogenic,
by further activating the tumor-infiltrating CD8þ T cells. In
fact, it has been shown that OX40 can directly costimulate
anti-CD3-activated CD8þ T cells and antigen-specific CD8þ
T cells in vitro (Taraban et al., 2002).
Recently, several studies have focused on the effect of
OX40 on the immunosuppressive population, that is, Tregs
and MDSCs. OX40 engagement has been shown to inhibit
Tregs in tumor tissues and exert antitumor activities (Piconese
et al., 2008; Hirschhorn-Cymerman et al., 2009). In contrast, it
was found that OX40 stimulation promotes Tregs in an
appropriate cytokine milieu (Ruby et al., 2009; Xiao et al.,
2012). The latter finding means that OX40 stimulation can
inhibit antitumor immune responses, depending on the tumor
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Figure 6. The OX40 agonist exerts antitumor effects on CD4þ
T-lymphodepleted tumors by further enhancing the cytotoxic activities of
effector cells. C57BL/6 mice (n¼ 5 per group) were subcutaneously inoculated
with B16F10 cells on day 0 and intratumorally administered anti-CD4 mAb or
control IgG on day 7. Some mice were administered OX86 on days 7 and 12.
On day 14, tumors were resected. (a) The numbers of myeloid-derived
suppressor cells (MDSCs), CD8þT cells, and natural killer (NK) cells within
tumor tissues were analyzed. Data shown are from one of two individual
experiments. (b) IL-2, IFN-g, granzyme B, and perforin mRNA levels were
determined and are shown relative to GAPDH mRNA levels. (*Po0.05;
**Po0.05; ***Po0.001). Data shown are from one of three individual
experiments. The bars represent meanþ SEM.
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cytokine milieu, via activation of Tregs. However, in our
model, OX40-stimulated Treg-mediated inhibition of
antitumor immune responses could be almost completely
avoidable in the initiation of OX40 agonist treatment,
because intratumoral administration with anti-CD4 mAb
efficiently depleted Tregs within tumors, along with helper T
cells (Supplementary Figure S1 online). On the other hand,
concerning MDSCs, OX40 agonist therapy has been found to
significantly enhance CD8þ T-cell infiltration and decrease
MDSC population in the MCA205 H12 tumor site. The
reduction in the number of MDSCs was caused by the indirect
effects of the OX40 agonist because OX40 expression in
MDSCs was not detected at the tumor site (Gough et al.,
2008). In our study, systemic treatment with the OX40 agonist
did not reduce the number of MDSCs that were recruited into
the tumor site following CD4þ T lymphodepletion (Figure 6a).
In contrast, OX40 agonist treatment further enhanced the
expression of arginase-1 and inducible nitric oxide synthase in
CD4þ T-lymphodepleted tumors, which may be indicative of
a more functionally active condition of MDSCs (Supple-
mentary Figure S4 online). We speculate that these functional
changes might occur in response to the enhancement of
cytotoxic activities of effector cells by the OX40 agonist.
The activation of MDSCs as a protective response might
increase with increase in the antitumor activities.
Although OX40 agonists seem to be promising candidates
for immunotherapy for human tumors (Weinberg et al., 2011),
the effects of OX40 agonist monotherapy for patients with
malignant tumors will be limited because most human tumors
are poorly immunogenic. On the other hand, several studies
have shown that autologous adoptive tumor-infiltrating
lymphocyte transfer after lymphodepletion can cause the
regression of refractory metastatic melanomas (Rosenberg
and Dudley, 2004; Dudley et al., 2005). Thus, our results
support the hypothesis that a combination of OX40 agonist
therapy and CD4þ T lymphodepletion might exert efficient
antitumor effects even on poorly immunogenic human
melanomas and suggest that lymphodepletion could
facilitate the accumulation of tumor-infiltrating lymphocytes
into tumors, thereby inducing antitumor effects; however, the
number of MDSCs might simultaneously increase within
tumors and be activated as a countermeasure against
accumulation and cytotoxicity mediated by tumor-infiltrating
lymphocytes. In conclusion, this combination therapy could
be a promising therapeutic strategy for patients with poorly
immunogenic melanomas and might be more effective if
further combined with therapeutic strategies that can
selectively deplete or inhibit MDSCs (Nagaraj et al., 2010;
Meyer et al., 2011; Kodumudi et al., 2012; Lesokhin et al.,
2012; Srivastava et al., 2012).
MATERIALS AND METHODS
Tumor cell lines and animal studies
B16F10 melanoma cells (provided by the RIKEN BRC through the
National Bio-resource Project of MEXT, Japan), IL-12 cDNA-trans-
fected B16F10 cells, and IL-27 cDNA-transfected B16F10 cells (Oniki
et al., 2006) were maintained in Eagle’s modified essential medium
supplemented with 5% fetal bovine serum. Cloudman S91 (clone
M-3) melanoma cells were obtained from American Type Culture
Collection (ATCC, Rockville, MD). C57BL/6N mice and DBA/2 mice
(6- to 8-week-old females) were purchased from Charles River
Laboratories (Tokyo, Japan). All animal experiments were
conducted according to the Guidelines for Animal Experimentation
at the Kobe University Graduate School of Medicine.
In vivo antibody treatments
We administered 500mg of rat GK1.5 mAb (ATCC) into the tumors on
day 7 after tumor inoculation to deplete CD4þ T cells. CD8þ T cells
in vivo were depleted using the rat mAb 2.43 (ATCC). NK cells were
depleted using a polyclonal anti-asialo GM1 antibody (Wako Fine
Chemicals, Osaka, Japan). OX40 agonist immunotherapy was per-
formed with a rat anti-OX40 agonistic mAb (OX86; ATCC). One
milligram of OX86 was administered intraperitoneally on day 0 or
day 7 and every 5 days thereafter. Rat IgG (Wako Fine Chemicals)
was used as the control antibody.
Flow cytometry
Resected tumors were digested with Liberase (0.2 Wunsch units/ml;
Roche Diagnostics K.K., Basel, Switzerland) and DNase I (0.02 mg/
ml; Roche) at 37 1C for 60 min. These cells were stained with different
combinations of the following antibodies: CD3-FITC, CD8-APC,
NK1.1-PE, CXCR3-PE-Cy7, CD11b-PE-Cy7, CCR2-APC (BioLegend,
San Diego, CA), CD4-FITC Gr-1-PE, Foxp3-PE (Miltenyi Biotec,
Bergisch Gladbach, Germany). Cytometric acquisition was performed
with a MoFlo XDP system (Beckman Coulter, Brea, CA) or BD
FACSVerse (BD Biosciences) and the Summit 5.2 (Beckman Coulter)
or Flowjo (Tree Star, Ashland, OR). Supplementary Figure S5 online
shows gating procedures of tumor samples.
Real-time quantitative reverse transcriptase–PCR (qRT-PCR)
analysis
Total RNA was extracted by using the QuickGene RNA tissue kit
(Fujifilm Corporation, Tokyo, Japan). cDNA synthesis was performed
using the PrimeScript RT reagent kit (Takara Bio, Shiga, Japan). Real-
time qRT-PCR was performed using an Applied Biosystems 7500 real-
time PCR system (Applied Biosystems, Foster City, CA) and SYBR
Premix Ex Taq II (Takara Bio). mRNA expression values were
normalized according to the internal control glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), and the relative expression
values were plotted.
Statistical analysis
The statistical significance of differences between the means of two
groups was determined using Student’s t-test. The statistical signifi-
cance of three or more groups was determined using Dunnett’s test or
Tukey’s HSD post hoc test. The differences were considered statisti-
cally significant at Po0.05. Data are shown as mean±SEM values.
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